Skip to main content
Top
Published in: Clinical Rheumatology 6/2017

01-06-2017 | Original Article

Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience

Authors: Gihyun Myung, Lindsy J. Forbess, Mariko L. Ishimori, Sumeet Chugh, Daniel Wallace, Michael H. Weisman

Published in: Clinical Rheumatology | Issue 6/2017

Login to get access

Abstract

Cardiovascular complications are a major cause of morbidity and even mortality among systemic lupus erythematosus (SLE) patients. Whether cardiac arrhythmias contribute to this burden among SLE patients, however, is not currently known. The goal of this study was to determine the prevalence of cardiac conduction abnormalities among SLE patients from a single center. We retrospectively reviewed the medical records of SLE patients who had 12-lead electrocardiograms (ECGs) available from various settings at a single academic center over the period of 10 years. In addition, ICD-9 codes for arrhythmias were obtained for the SLE patients whose ECGs were reviewed. The hospital setting (in-patient, out-patient, emergency department) and the indication for obtaining the ECG were evaluated. Two hundred thirty-five SLE patients had available ECGs. Sinus tachycardia was most common (18%). With direct ECG review, tachyarrhythmias were found in 6% of SLE patients, with the most common being atrial fibrillation (3%). Atrial fibrillation was seen even more frequently (9%) when ICD-9 codes were reviewed. No patients had brady-arrhythmias. QT prolongation was present in 17% of patients upon direct ECG review. More ECGs with tachyarrhythmias and QT prolongation were found among inpatients, with preoperative evaluation and gastrointestinal symptoms being the most common indications. Sinus tachycardia was the most common finding seen among our SLE patients with ECGs. Further study into the possible mechanisms behind this is warranted, including the possibility of autonomic nervous system involvement in SLE.
Literature
2.
go back to reference Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009) Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum 61:1396–1402. doi: 10.1002/art.24537 Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH (2009) Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses’ health study. Arthritis Rheum 61:1396–1402.​ doi: 10.​1002/​art.​24537
4.
go back to reference Benjamin EJ, D’Agostino RB, Silbershatz H, Kannel WB, Levy DWPA (1998) Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98(10):946–952 Benjamin EJ, D’Agostino RB, Silbershatz H, Kannel WB, Levy DWPA (1998) Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98(10):946–952
5.
go back to reference Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 164(9):943–948. doi:10.1001/archinte.164.9.943 CrossRefPubMed Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH (2004) Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 164(9):943–948. doi:10.​1001/​archinte.​164.​9.​943 CrossRefPubMed
6.
go back to reference Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18):2370–2375. doi:10.1001/jama.285.18.2370 CrossRefPubMed Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18):2370–2375. doi:10.​1001/​jama.​285.​18.​2370 CrossRefPubMed
8.
go back to reference US Department of Health and Human Services Food and Drug Administration (2005). Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs US Department of Health and Human Services Food and Drug Administration (2005). Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs
10.
15.
go back to reference Bourre-Tessier J, Urowitz MB, Clarke AE et al (2014) Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). doi:10.1002/acr.22370 Bourre-Tessier J, Urowitz MB, Clarke AE et al (2014) Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). doi:10.​1002/​acr.​22370
16.
go back to reference Gómez-Barrado JJ, García-Rubira JC, Polo Ostáriz MA, Turégano Albarrán S (2002) Complete atrioventricular block in a woman with systemic lupus erythematosus. Int J Cardiol 82(3):289–292CrossRefPubMed Gómez-Barrado JJ, García-Rubira JC, Polo Ostáriz MA, Turégano Albarrán S (2002) Complete atrioventricular block in a woman with systemic lupus erythematosus. Int J Cardiol 82(3):289–292CrossRefPubMed
Metadata
Title
Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience
Authors
Gihyun Myung
Lindsy J. Forbess
Mariko L. Ishimori
Sumeet Chugh
Daniel Wallace
Michael H. Weisman
Publication date
01-06-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 6/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3582-0

Other articles of this Issue 6/2017

Clinical Rheumatology 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine